Strengths

Livanova’s ROIC of about 10.2% indicates better capital efficiency than many medtech peers, supporting durable value creation despite mixed operating leverage.

A net debt to EBITDA ratio below zero implies net cash, giving LIVN more balance-sheet flexibility than leveraged device peers and reducing refinancing pressure.

A current ratio of 1.45 and quick ratio of 1.21 suggest adequate near-term liquidity, which is stronger than weaker peers that operate with tighter working-capital buffers.

The company’s broad cardiopulmonary and neuromodulation exposure can diversify demand versus more concentrated peers, lowering dependence on any single procedure category.

Weaknesses

A cash conversion cycle above 111 days signals heavy working-capital absorption, leaving LIVN less efficient than faster-turning peers in converting sales into cash.

The absence of disclosed margin metrics limits evidence of operating leverage, while peers with clearer margin expansion profiles appear structurally better positioned.

A debt-to-equity ratio of 0.27 is manageable, but it still leaves LIVN less conservatively financed than net-cash peers with stronger balance-sheet optionality.

Limited visibility on multi-year growth and segment concentration makes it harder to demonstrate a peer-leading structural edge in demand durability.

Opportunities

If LIVN improves working-capital discipline, cash generation could rise faster than peers, strengthening reinvestment capacity without requiring proportional revenue growth.

Further capitalizing on cardiopulmonary and neuromodulation installed bases could lift recurring revenue mix versus peers with more transactional demand profiles.

Incremental clinical adoption and procedure recovery in core franchises could support share gains if execution outpaces larger diversified medtech competitors.

Balance-sheet flexibility from net cash can support targeted investment, which may help LIVN close capability gaps versus better-scaled peers over time.

Threats

Larger medtech peers with broader commercial reach can outspend LIVN on evidence generation and sales coverage, pressuring relative positioning in core categories.

Prolonged working-capital intensity can constrain cash deployment, making LIVN more vulnerable than peers if demand softens or reimbursement timing worsens.

If operating margins remain opaque or lag peers, investors may continue to assign LIVN a discount despite acceptable capital efficiency.

Concentration in specialized hospital procedures leaves LIVN exposed to competitive product cycles and utilization volatility versus more diversified device peers.

Overall Score

LIVN shows a solid balance sheet and acceptable capital efficiency, but working-capital intensity and limited evidence of superior margin structure keep its peer-relative positioning moderate.